Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 11/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7024944 | 0.88 | ADRB1 (0.50) | ADRB1ADRB3ADRB2ATMKDM4E | |
| SCHEMBL7027312 | 0.81 | MEN1 (0.65) | ADRB1ADRB3ADRB2ATMCYP1A2 | |
| SCHEMBL7032501 | 0.80 | ALDH1A1 (0.51) | ADRB1ADRB3ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL7028479 | 0.79 | RXFP1 (0.42) | ATMKDM4EMEN1KMT2A | |
| SCHEMBL7608531 | 0.79 | ADRB1 (0.42) | ADRB1ADRB3ADRB2KDM4EALDH1A1 | |
| SCHEMBL6320450 | 0.78 | CASR (0.58) | ADRB1ADRB3ADRB2ATMKDM4E | |
| SCHEMBL6326406 | 0.78 | CASR (0.58) | ADRB1ADRB3ADRB2ATMKDM4E | |
| SCHEMBL7033981 | 0.75 | MEN1 (0.70) | ADRB1ADRB3ADRB2ATMMEN1 | |
| SCHEMBL6327240 | 0.75 | MEN1 (0.70) | ADRB1ADRB3ADRB2ATMMEN1 | |
| Hydrochloric Acid SCHEMBL7027080 | 0.74 | MEN1 (0.68) | ADRB1ADRB3ADRB2MEN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030032834-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1257528-A1 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001060786-A1 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032834-A1 | Aminoalcohol derivatives | ADRB1, ADRB2, ADRB3 | ADRB1 1/4885ADRB3 3/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.